Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

BEAT B-cell Lymphoma: Biomarkers of Effective CART19 Assessed in the Tissue Microenvironment

Project description

Predictive biomarkers for immunotherapy response in B-cell lymphoma

B-cell lymphomas are haematological malignancies originating from B lymphocytes. A promising therapy has recently emerged based on T cells genetically modified to express a chimeric antigen receptor (CAR) targeting CD19 on B lymphocytes. This redirects the immune system to attack malignant cells. Funded by the Marie Skłodowska-Curie Actions programme, the BEAT B-cell Lymphoma project focuses on the interaction among CART-cells and malignant cells within the tumour microenvironment. The key objective is to discover new biomarkers for real-time feedback on CART therapy response. These biomarkers will help predict outcomes and refine patient selection for clinical trials, ultimately enhancing the efficacy of CART therapy and its effects on patient tissues.

Objective

"Project Title: BEAT B-cell Lymphoma: Biomarkers of Effective CART19 Assessed in Tissue microenvironment

B-cell lymphomas, encompassing Follicular Lymphoma (FL) and Large B-cell Lymphoma (LBCL), pose significant health concerns. While the use of T-cells modified with a chimeric antigen receptor targeting CD19 (CART19) offers a potential breakthrough in treating these malignancies, it is imperative to unravel the intricate dynamics between the CART19 and the tumor B-cells within their unique tissue microenvironment (TME).

The ""BEAT B-cell Lymphoma"" initiative is poised to transform lymphoma therapeutic strategies. More than just advancing the status quo, this project is geared towards unveiling novel biomarkers that facilitate immediate feedback on therapeutic outcomes. These newfound markers will empower clinicians and patients with predictive tools for CART19 interventions and serve as cornerstones for redefining inclusion criteria in subsequent clinical trials. But the ambition of this endeavor goes beyond mere biomarker discovery. It promises in-depth revelations on how CART19 impacts actual patient-derived tissues, deepening our knowledge and inspiring fresh treatment avenues. The short term concrete vision? Fine-tuning CART19's performance and honing the initial patient selection process.

As a medical doctor with a specialization in hematopathology, I've offered numerous diagnoses of B-cell lymphomas, grounded in histological and molecular markers predominantly sourced from tumor B-cells. My foundational training as an immunologist has sharpened my curiosity, drawing my attention to the often underemphasized tissue microenvironment. My affinity for bioinformatics further equips me to navigate and interpret vast datasets efficiently. To ensure the success of this project and to further my journey towards becoming an independent researcher, I partnered with the renowned Alizadeh Lab at Stanford, USA and will later join the de Miranda lab in the Netherlands."

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-GF - HORIZON TMA MSCA Postdoctoral Fellowships - Global Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2023-PF-01

See all projects funded under this call

Coordinator

ACADEMISCH ZIEKENHUIS LEIDEN
Net EU contribution
€ 296 296,32
Address
ALBINUSDREEF 2
2333 ZA Leiden
Netherlands
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Partners (1)